Konstantin Adamsky

Direttore/Membro del Consiglio presso FILAMENT HEALTH CORP.

53 anni

Health Technology

Consumer Services

Posizioni attive di Konstantin Adamsky

Società	Posizione	Inizio	Fine
FILAMENT HEALTH CORP.	Direttore/Membro del Consiglio	23/08/2022	-
FILAMENT HEALTH CORP.	Independent Dir/Board Member	23/08/2022	-

Società	Posizione	Inizio	Fine
Regenera Pharma Ltd. Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel.	Amministratore Delegato	-	01/08/2017
	Direttore operativo	01/08/2017	01/10/2020
Levco Pharmaceuticals Ltd.	Direttore operativo	-	-

Weizmann Institute of Science

Doctorate Degree

Distribuzione geografica

Israele	4
Canada	2

Posizioni

Settori

Health Technology	3
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
FILAMENT HEALTH CORP.	Health Technology

Aziende private	2
Regenera Pharma Ltd. Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel.	Health Technology
Levco Pharmaceuticals Ltd.

Aziende private

Health Technology

Levco Pharmaceuticals Ltd.